This website is intended for healthcare professionals only.

Hospital Healthcare Europe
Hospital Pharmacy Europe     Newsletter          
HOPE LOGO

Dermatology

IL-17 a potential therapeutic target in chronic urticaria
IL-17 a potential therapeutic target in chronic urticaria
Read more
Can daily application of an emollient from birth prevent the development of atopic eczema?
Can daily application of an emollient from birth prevent the development of atopic eczema?
Read more
Expert view: Sunbed use and melanoma – is there really a link?
Expert view: Sunbed use and melanoma – is there really a link?
Read more
Dupilumab approved by EC for adolescents with moderate-to-severe atopic dermatitis
Dupilumab approved by EC for adolescents with moderate-to-severe atopic dermatitis
Read more
Multiple genes affect risk of asthma, hay fever and eczema
Multiple genes affect risk of asthma, hay fever and eczema
Read more
Common skin bacterium puts children with severe eczema at higher risk of food allergy
Common skin bacterium puts children with severe eczema at higher risk of food allergy
Read more
Urticaria: not always an allergic reaction
Urticaria: not always an allergic reaction
Read more
EU reapproves Cimzia to treat plaque psoriasis
EU reapproves Cimzia to treat plaque psoriasis
Read more
Initiative launched to improve people’s understanding of eczema
Initiative launched to improve people’s understanding of eczema
Read more
NICE Final Appraisal Determination for guselkumab to treat moderate to severe plaque psoriasis
NICE Final Appraisal Determination for guselkumab to treat moderate to severe plaque psoriasis
Read more
NICE issues draft guidance not recommending dupilumab
NICE issues draft guidance not recommending dupilumab
Read more
Omalizumab recommended in global chronic urticaria guideline
Omalizumab recommended in global chronic urticaria guideline
Read more
New data demonstrates long-term skin clearance in patients treated with guselkumab
New data demonstrates long-term skin clearance in patients treated with guselkumab
Read more
NICE Final Appraisal Determination recommends use of brodalumab as cost-effective
NICE Final Appraisal Determination recommends use of brodalumab as cost-effective
Read more
New two-year data for guselkumab following positive CHMP opinion
New two-year data for guselkumab following positive CHMP opinion
Read more
Brodalumab receives license from the European Commission
Brodalumab receives license from the European Commission
Read more
Marketing authorisation for dupilumab in moderate to severe atopic dermatitis recommended
Marketing authorisation for dupilumab in moderate to severe atopic dermatitis recommended
Read more

Popular articles

EUSEM: Diagnostic ability of ChatGPT comparable to emergency department clinicians
Ensitrelvir shows benefits for Covid-19 and long Covid in two studies
Ceiling-mounted IR systems: facilitating same-day prostate artery embolisation





 

Download Hospital Healthcare Europe free app

Download our app from the Apple App Store Download our app from Google Play

In official association with

HOPE Logo Footer

© Cogora 2023
Cogora Limited. 1 Giltspur Street, London EC1A 9DD Registered in the United Kingdom. Reg. No. 2147432

Cogora
×